[Pharmacologic studies on the new antitussive agent, 3-(2,2-diphenylethyl)-5-(2-piperidinoethyl)-1,2,4-oxadiazole].
D000818:Animals; D000996:Antitussive Agents / Q000627:therapeutic use* / Q000633:toxicity; D002415:Cats; D003061:Codeine / Q000627:therapeutic use; D003371:Cough / Q000188:drug therapy*; D006168:Guinea Pigs; D066298:In Vitro Techniques; D051379:Mice; D010069:Oxadiazoles / Q000627:therapeutic use* / Q000633:toxicity; D010208:Papaverine / Q000627:therapeutic use; D051381:Rats
D000996:Antitussive Agents; D010069:Oxadiazoles; D010208:Papaverine; D003061:Codeine
Pharmakologische Untersuchung des neuen Antitussivums 3-(2,2-Diphenyläthyl)-5-(2-piperidinoäthyl)-1,2,4-oxadiazol.